GlassScriptPhysician profile
Lucy Roberts
NPI 1275642043
$2,711.50
in general payments reported to CMS, 2019-2025
30 companies · $19.83 in 2025
The $19.83 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,392 · 2022: $709 · 2023: $383 · 2024: $208 · 2025: $19.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $580.00 | 2021-2025 | Omnipod |
| Abbott Laboratories | $401.58 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $271.12 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $202.78 | 2021-2022 | |
| Lilly USA, LLC | $125.02 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.18 | 2021-2022 | |
| Medtronic, INC. | $104.86 | 2021-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $77.32 | 2021 | |
| Esperion Therapeutics, INC. | $77.11 | 2021 | |
| Cequr Corporation | $74.36 | 2021 | |
| Abbvie INC. | $71.98 | 2021-2023 | |
| Amarin Pharma, INC. | $60.43 | 2021 | |
| Antares Pharma, INC. | $56.32 | 2021-2022 | |
| Dexcom, INC. | $55.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.48 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $38.71 | 2021 | |
| Tandem Diabetes Care, INC. | $38.14 | 2021 | |
| Amneal Pharmaceuticals LLC | $37.44 | 2021-2022 | |
| Novo Nordisk INC | $34.06 | 2021-2022 | |
| Zealand Pharma US, INC. | $33.46 | 2021-2022 | |
| Vistapharm, INC. | $31.11 | 2021 | |
| Acerus Pharmaceuticals Corporation | $29.46 | 2021 | |
| Radius Health, INC. | $24.30 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.50 | 2021 | |
| Merck Sharp & Dohme LLC | $17.90 | 2021 | |
| Clarus Therapeutics INC. | $17.68 | 2021 | |
| Grt US Holding, INC. | $16.25 | 2021 | |
| Mannkind Corporation | $16.10 | 2021 | |
| Lifescan, INC. | $15.63 | 2021 | |
| Corcept Therapeutics | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.